
## Diabetes


Charles Brackett, MD, MPH

## Diabetes Mellitus



## **Types of Diabetes**

- Type 1 (5%): Autoimmune destruction of β cells
  - "juvenile onset"
  - "insulin dependent" DKA
- Type 2 (95%): Insulin resistance
  - "adult onset"
  - "non-insulin dependent" (but often on insulin)
  - Strongly genetic (90% concordance in identical twins)
  - Strongly related to lifestyle
    - "Diabesity epidemic"



## Diagnostic Criteria


- FBS>126 mg/dl (on 2 occasions)
- RBS>200 with symptoms
- OGTT with glucose>200 2 hours after load
- HgbA1c>6.5
- "Prediabetes": FBS 100-125, A1c 5.8-6.4

# **Short Term Complications**


- Symptoms of hyperglycemia
  - Polyuria/polydipsia, weight loss
  - Immune dysfunction
- Diabetic ketoacidosis (Type 1)
  - Lack of insulin +/or stress
  - Hyperglycemia → diuresis → dehydration
  - Ketosis due to insulin deficiency 
    burn fatty acids
  - Sx: n/v, abd pain, Kussmaul respirations, Δ MS
- Hyperosmolar nonketotic state
  - Extreme hyperglycemia  $\rightarrow$  volume depletion and  $\triangle$  MS

# **Long Term Complications**


- Microvascular
  - Retinopathy
  - Nephropathy
  - Neuropathy



- Macrovascular (atherosclerosis)
  - Ischemic heart disease: MI
  - Cerebrovascular disease: Stroke
  - PVD: amputation



# Reducing the Risk of Diabetic Complications Is Essential



## **Prevention of Complications**

- Glycemic Control
- Blood Pressure Control
- Lipid Control (statins)
- Aspirin (risk>10%/10 years)
- Smoking cessation
- Screening for:

  - Nephropathy > urine for albumin/creatinine
  - Neuropathy > foot inspection/monofilament

# **Glycemic Control**

## Usual goal is A1c<7</p>

## Monotherapy Metformin

Lifestyle Management

| EFFICACY*    | high               |
|--------------|--------------------|
| HYPO RISK    | low risk           |
| WEIGHT       | neutral/loss       |
| SIDE EFFECTS | GI/lactic acidosis |
| COSTS*       | low                |

If A1C target not achieved after approximately 3 months of monotherapy, proceed to 2-drug combination (order not meant to denote any specific preference — choice dependent on a variety of patient- & disease-specific factors):

## **Dual Therapy**

### Metformin +

## Lifestyle Management

|              | Sulfonylurea  | Thiazolidinedione | DPP-4 inhibitor | SGLT2 inhibitor      | GLP-1 receptor agonist | Insulin (basal) |
|--------------|---------------|-------------------|-----------------|----------------------|------------------------|-----------------|
| EFFICACY*    | high          | high              | intermediate    | intermediate         | high                   | highest         |
| HYPO RISK    | moderate risk | low risk          | low risk        | low risk             | low risk               | high risk       |
| WEIGHT       | gain          | gain              | neutral         | loss                 | loss                   | gain            |
| SIDE EFFECTS | hypoglycemia  | edema, HF, fxs    | rare            | GU, dehydration, fxs | GI                     | hypoglycemia    |
| COSTS*       | low           | low               | high            | high                 | high                   | high            |

If ATC target not achieved after approximately 3 months of dual therapy, proceed to 3-drug combination (order not meant to denote any specific preference — choice dependent on a variety of patient- & disease-specific factors):

### Triple Therapy

#### Metformin +

### Lifestyle Management

| Sulfonylurea + 1 |                      | This | Thiazolidinedione +  |    | DPP-4 inhibitor +    |    | SGLT2 inhibitor +    |    | GLP-1 receptor agonist + |    | Insulin (basal) + |  |
|------------------|----------------------|------|----------------------|----|----------------------|----|----------------------|----|--------------------------|----|-------------------|--|
|                  | TZD                  |      | SU                   |    | SU                   |    | SU                   |    | SU                       |    | TZD               |  |
| 01               | DPP-4-i              | or   | DPP-4-i              | or | TZD                  | or | TZD                  | or | TZD                      | or | DPP-4-i           |  |
| 01               | SGLT2-i              | or   | SGLT2-i              | or | SGLT2-i              | or | DPP-4-i              | or | SGLT2-i                  | or | SGLT2-i           |  |
| 01               | GLP-1-RA             | or   | GLP-1-RA             | or | Insulin <sup>6</sup> | or | GLP-1-RA             | or | Insulin <sup>s</sup>     | or | GLP-1-RA          |  |
| 01               | Insulin <sup>6</sup> | or   | Insulin <sup>6</sup> |    |                      | or | Insulin <sup>s</sup> |    |                          |    |                   |  |

# Treatment of hypoglycemia

- Sx: HA, visual changes, ΔMS, seizure, autonomic activation: tremor, sweating, palpitations.
- If awake- give glucose tab, juice....
- If severe, not taking po- 25-50g of D50 IV
- If no IV- glucagon 0.5-1mg IM or SC

# Diabetes (or any chronic disease!) and Behavioral Health

- Importance of patient self-management
  - Adherence with medications, follow-up
  - Adherence with lifestyle changes
- Behavioral Health issues can interfere
  - Motivation, helplessness, trust, organizational skills, stigma/shame, denial/delusional beliefs
- Social Determinants of health can interfere
  - Financial barriers, access to healthy food, exercise...
  - Hierarchy of needs
- Additional Risks
  - Smoking
  - Antipsychotic medications have metabolic SEs:
    - Weight gain, hyperlipidemia, hyperglycemia, htn